UM  > 健康科學學院
The roles of doxorubicin in hepatocellular carcinoma
Kin Tam
2013
Source PublicationADMET & DMPK
ISSN1848-7718
Volume1Issue:3Pages:29-44
Abstract

Liver cancer is the third most common cause of death from cancer worldwide. Hepatocellular carcinoma (HCC) accounts for 80 – 90 % of all primary liver cancers. The mortality of HCC is high, and the treatment options are limited. Doxorubicin exhibits a broad spectrum of anti-tumour activity. When administrated via the hepatic artery, doxorubicin showed anti-tumour effects and partial response in HCC patients. In this mini review, we will first outline the treatment options for HCC. Then, we will briefly discuss the pharmacological, toxicological and pharmacokinetic aspects of doxorubicin. Finally, we will review the new developments and future directions of using doxorubicin in the therapy of HCC.

KeywordPrimary Liver Cancer Anticancer Cytotoxic Drug Transarterial Chemoembolization Drug Eluting Beads
DOIhttp://doi.org/10.5599/admet.1.3.7
Language英语
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionFaculty of Health Sciences
AffiliationFaculty of Health Science, University of Macau, Macau, China
First Author AffilicationUniversity of Macau
Recommended Citation
GB/T 7714
Kin Tam. The roles of doxorubicin in hepatocellular carcinoma[J]. ADMET & DMPK,2013,1(3):29-44.
APA Kin Tam.(2013).The roles of doxorubicin in hepatocellular carcinoma.ADMET & DMPK,1(3),29-44.
MLA Kin Tam."The roles of doxorubicin in hepatocellular carcinoma".ADMET & DMPK 1.3(2013):29-44.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Kin Tam]'s Articles
Baidu academic
Similar articles in Baidu academic
[Kin Tam]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Kin Tam]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.